47
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      scite_
       
      • Record: found
      • Abstract: found
      • Conference Proceedings: found
      Is Open Access

      Targeting Signalling Modules in Thyroid Cancer

      Published
      conference-abstract
      Bookmark

            Abstract

            Advanced thyroid cancer patients have limited treatment options and rarely result in a cure of the disease [1]. The most challenging patient groups to treat are radioiodine refractory, poorly differentiated and anaplastic thyroid cancer patients in specific. These tumors are often inoperable and resistant to conventional therapy. Therefore, these patients are in unmet need for novel treatment options. Targeting cancer with single drugs has generally not been successful in the past years. Tumors often show initial response to treatment, but eventually progress on treatment. In thyroid cancer, Lenvatinib, an oral multi kinase inhibitor, has demonstrated improvements in progression free survival but not overall survival [2]. Therefore, it is highly anticipated that the solution is combination therapy by targeting tumors simultaneously from several angles, in a synergistic manner. In the context of REPO4EU, thyroid cancer is one of the model diseases to test the hypotheses of network medicine using repurposable drugs [3]. Highly interconnected thyroid cancer modules have been constructed in silico based on systematic literature searches containing next generation sequencing (NGS) data and drug-target databases. Consequently, in vitro validation is currently being performed in thyroid cancer cell lines to validate drug repurposing compounds and identify synergistic combination therapies. To ultimately test the concept of network pharmacology based drugs repurposing in vivo, a proof of concept clinical trial is planned. Furthermore, to efficiently stratify patients in the clinic that might be amendable towards a drug repurposing approach, REPO4EU will attempt to use AI to identify patients that will not respond to radioiodine therapy. The current study aims to validate network medicine based drug repurposing in thyroid cancer, and several topics regarding the goals of REPO4EU in thyroid cancer are discussed.

            Content

            Author and article information

            Conference
            RExPO24 Conference
            REPO4EU
            4 June 2024
            Affiliations
            [1 ] Radboud University Medical Center, Department of Internal Medicine, Nijmegen, The Netherlands ( https://ror.org/05wg1m734)
            [2 ] Maastricht University, Pharmacology and Personalised Medicine, Maastricht, The Netherlands ( https://ror.org/02jz4aj89)
            [3 ] Technical University of Munich, Department of Animal Physiology and Immunology, School of Life Sciences, Freising, Germany ( https://ror.org/02kkvpp62)
            [4 ] University Hospital Essen, Department of Neurology, Essen, Germany ( https://ror.org/02na8dn90)
            Author notes
            Author information
            https://orcid.org/0009-0004-5892-8706
            https://orcid.org/0000-0002-4201-7973
            https://orcid.org/0000-0002-9356-7940
            https://orcid.org/0000-0002-0935-074X
            https://orcid.org/0000-0001-6994-493X
            https://orcid.org/0000-0001-7473-8321
            https://orcid.org/0000-0003-0419-5549
            https://orcid.org/0000-0002-9603-0460
            Article
            10.58647/REXPO.24000069.v1
            826666a5-b213-4fe7-b2e8-592affed3e1c

            This work has been published open access under Creative Commons Attribution License CC BY 4.0 , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Conditions, terms of use and publishing policy can be found at www.scienceopen.com .

            RExPO24
            3
            Munich, Germany
            3-5 July 2024
            History
            : 4 June 2024
            Product

            REPO4EU

            Categories

            The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
            Life sciences
            Thyroid carcinoma,pre-clinical,clinical,drug repurposing,network medicine,modules

            Comments

            Comment on this article